Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Eton Pharmaceuticals stock price, quote, forecast and news

ETON
US29772L1089
A2N38G

Price

4.54
Today +/-
+0.26
Today %
+6.60 %
P

Eton Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Eton Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Eton Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Eton Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Eton Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Eton Pharmaceuticals Stock Price History

DateEton Pharmaceuticals Price
8/23/20244.54 undefined
8/22/20244.25 undefined
8/21/20244.14 undefined
8/20/20244.12 undefined
8/19/20244.04 undefined
8/16/20244.03 undefined
8/15/20244.01 undefined
8/14/20244.06 undefined
8/13/20243.77 undefined
8/12/20243.75 undefined
8/9/20243.72 undefined
8/8/20243.62 undefined
8/7/20243.49 undefined
8/6/20243.50 undefined
8/5/20243.52 undefined
8/2/20243.58 undefined
8/1/20243.63 undefined
7/31/20243.60 undefined
7/30/20243.54 undefined
7/29/20243.54 undefined

Eton Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Eton Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Eton Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Eton Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Eton Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Eton Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Eton Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Eton Pharmaceuticals’s growth potential.

Eton Pharmaceuticals Revenue, EBIT and net profit per share

DateEton Pharmaceuticals RevenueEton Pharmaceuticals EBITEton Pharmaceuticals Net Income
2026e129.21 M undefined10.89 M undefined20.87 M undefined
2025e48.35 M undefined7.75 M undefined5.76 M undefined
2024e37.23 M undefined-1.33 M undefined-3.93 M undefined
202331.64 M undefined-1.19 M undefined-936,000 undefined
202221.25 M undefined-8.75 M undefined-9.02 M undefined
202121.83 M undefined-1.5 M undefined-1.96 M undefined
202040,000 undefined-27.11 M undefined-27.97 M undefined
2019960,000 undefined-18.6 M undefined-18.32 M undefined
20180 undefined-10.32 M undefined-37.23 M undefined
20170 undefined-7.15 M undefined-8.64 M undefined

Eton Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e
00002121313748129
------47.6219.3529.73168.75
----90.4866.6767.74---
0000191421000
-7-10-18-27-1-8-1-1710
-----4.76-38.10-3.23-2.7014.587.75
-8-37-18-27-1-90-3520
-362.50-51.3550.00-96.30800.00---266.67300.00
16.3217.6117.7621.0125.2125.1525.65000
----------
Details

Keystats

ⓘ

Revenue and Growth

The Eton Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Eton Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (k)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2017201820192020202120222023
13.1626.7412.0721.314.4116.3121.39
000.470.055.471.853.41
0000000
000.381.240.550.560.91
0.140.772.092.123.181.291.13
13.327.5115.0124.7123.6120.0126.84
0.120.771.2810.220.260.15
0000000
0000000
000.730.583.624.754.74
0000000
30506040201012
0.150.822.071.623.865.024.9
13.4528.3317.0826.3327.4725.0331.74
19.010.020.020.020.030.030.03
1.7672.1574.72107.8111.72116.19119.52
-8.64-45.87-64.19-92.16-94.11-103.13-104.07
0000000
0000000
12.1326.310.5515.6617.6413.0915.48
0.541.420.582.341.771.691.85
0.250.61.391.171.373.749.01
0000000
0000000
0000.281.421.035.38
0.792.021.973.794.566.4616.24
004.546.765.265.380
0000000
5200201002011022
0.5204.566.865.285.490.02
1.312.026.5310.659.8411.9516.26
13.4428.3217.0826.3127.4825.0431.74
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Eton Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Eton Pharmaceuticals's financial health and stability.

Assets

Eton Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Eton Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Eton Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Eton Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
-7-12-18-27-1-90
000001,0000
0000000
00-21-673
1636683
0000000
0000000
-4-8-18-22-446
00-10-3-20
00-10-2-20
0000000
0000000
004200-1
1822029000
1821531000
-------
0000000
1313-149-615
-4.85-8.39-19.88-22.4-7.982.036.04
0000000

Eton Pharmaceuticals stock margins

The Eton Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Eton Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Eton Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Eton Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Eton Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Eton Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Eton Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Eton Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Eton Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Eton Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Eton Pharmaceuticals Margin History

Eton Pharmaceuticals Gross marginEton Pharmaceuticals Profit marginEton Pharmaceuticals EBIT marginEton Pharmaceuticals Profit margin
2026e66.56 %8.43 %16.15 %
2025e66.56 %16.03 %11.92 %
2024e66.56 %-3.56 %-10.56 %
202366.56 %-3.77 %-2.96 %
202267.39 %-41.18 %-42.45 %
202187.08 %-6.87 %-8.98 %
2020-625 %-67,775 %-69,925 %
201953.13 %-1,937.5 %-1,908.33 %
201866.56 %0 %0 %
201766.56 %0 %0 %

Eton Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Eton Pharmaceuticals earnings per share therefore indicates how much revenue Eton Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Eton Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Eton Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Eton Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Eton Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eton Pharmaceuticals Revenue, EBIT and net profit per share

DateEton Pharmaceuticals Sales per ShareEton Pharmaceuticals EBIT per shareEton Pharmaceuticals Earnings per Share
2026e5.03 undefined0 undefined0.81 undefined
2025e1.88 undefined0 undefined0.22 undefined
2024e1.45 undefined0 undefined-0.15 undefined
20231.23 undefined-0.05 undefined-0.04 undefined
20220.84 undefined-0.35 undefined-0.36 undefined
20210.87 undefined-0.06 undefined-0.08 undefined
20200 undefined-1.29 undefined-1.33 undefined
20190.05 undefined-1.05 undefined-1.03 undefined
20180 undefined-0.59 undefined-2.11 undefined
20170 undefined-0.44 undefined-0.53 undefined

Eton Pharmaceuticals business model

The company Eton Pharmaceuticals Inc is an innovative company that specializes in the development of high-quality and reliable medications. The company was founded in 2017 in Deer Park, Illinois, and has since become a leading company in the pharmaceutical industry. Eton Pharmaceuticals Inc's business model is closely related to the development of new medications. The company specializes in the development of so-called "gel-coated" medications, which have better efficacy and tolerability than conventional medications. The company uses innovative and patented technologies to overcome the current limitations of medications and provide customers with the best possible treatment. Eton Pharmaceuticals Inc has different divisions for the development of medications. One of the most important divisions is oncology, where medications for tumor treatment are developed. The company relies on innovative approaches to discover new active substances and improve the treatment of cancer patients. In addition, the company has extensive experience in the production of antibiotics. Eton Pharmaceuticals Inc has developed its own products tailored to the needs of patients, promising fast and effective effects. The company has also developed special medications for the treatment of cardiovascular diseases, aiming to provide patients with a better quality of life. One of the products offered by Eton Pharmaceuticals Inc is the medication "BML-190". This medication is an anti-inflammatory drug used for pain and inflammation. Its special feature is its high effectiveness with minimal side effects, which often occur with other medications. Another product of Eton Pharmaceuticals Inc is the medication "DS-300", used for certain eye diseases. The medication contains an active substance that acts on the eyes and allows for quick healing. Thanks to the innovative technology used in its development, this medication is well tolerated and has minimal side effects. Overall, Eton Pharmaceuticals Inc is an innovative company specializing in the development of high-quality medications. With its business model and expertise in various areas of the pharmaceutical industry, the company is well equipped to continue making significant contributions to healthcare. Eton Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Eton Pharmaceuticals SWOT Analysis

Strengths

1. Strong product portfolio comprising a diverse range of pharmaceuticals.

2. Well-established presence in the pharmaceutical industry.

3. Robust distribution network, ensuring wide market reach.

Weaknesses

1. Relatively small market share compared to larger pharmaceutical companies.

2. Limited financial resources for research and development.

3. Vulnerability to changes in regulatory environment and pricing pressures.

Opportunities

1. Potential for expansion into emerging markets with increasing healthcare needs.

2. Growing demand for specialized pharmaceuticals targeting specific medical conditions.

3. Collaborations and partnerships with other pharmaceutical companies for joint product development.

Threats

1. Intense competition from larger pharmaceutical companies with greater resources.

2. Regulatory challenges and stringent approval processes for new drug releases.

3. Fluctuations in healthcare policies and reimbursement systems impacting pricing and market access.

Eton Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Eton Pharmaceuticals historical P/E ratio, EBIT, and P/S ratio.

Eton Pharmaceuticals shares outstanding

The number of shares was Eton Pharmaceuticals in 2023 — This indicates how many shares 25.645 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Eton Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Eton Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Eton Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Eton Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Eton Pharmaceuticals.

Eton Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.07 -0.12  (-68.07 %)2024 Q2
3/31/2024-0.05 -0.03  (34.64 %)2024 Q1
12/31/2023-0.04 -0.09  (-120.59 %)2023 Q4
9/30/2023-0.1 -0.02  (80.39 %)2023 Q3
6/30/2023-0.09 0.15  (263.4 %)2023 Q2
3/31/2023-0.14 -0.1  (29.97 %)2023 Q1
12/31/20220.01 0.04  (292.16 %)2022 Q4
9/30/2022-0.15 -0.12  (21.57 %)2022 Q3
6/30/20220.03 -0.06  (-296.08 %)2022 Q2
3/31/2022-0.08 -0.21  (-157.35 %)2022 Q1
1
2
3

Eulerpool ESG Scorecard© for the Eton Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

31/ 100

🌱 Environment

33

👫 Social

42

🏛️ Governance

19

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Eton Pharmaceuticals list of shareholders

%
Name
Stocks
Change
Date
9.85 % Opaleye Management Inc.2,529,88799,61712/31/2023
7.72 % Harrow Health, Inc.1,982,00004/14/2023
4.18 % Brynjelsen (Sean E)1,074,9405,0004/14/2023
4.00 % The Vanguard Group, Inc.1,027,68851,25212/31/2023
2.23 % Westside Investment Management, LLC573,96010,8503/31/2024
1.92 % Acuitas Investments LLC492,054273,05412/31/2023
1.17 % Paradigm Capital Management, Inc.300,000012/31/2023
1.09 % BlackRock Institutional Trust Company, N.A.281,006-47912/31/2023
0.99 % Bridgeway Capital Management, LLC253,362-18,10012/31/2023
0.88 % Geode Capital Management, L.L.C.227,2569,62712/31/2023
1
2
3
4
5
...
9

Eton Pharmaceuticals Executives and Management Board

Mr. Sean Brynjelsen51
Eton Pharmaceuticals President, Chief Executive Officer, Director (since 2017)
Compensation 2.12 M
Mr. James Gruber51
Eton Pharmaceuticals Chief Financial Officer, Treasurer, Company Secretary
Compensation 712,845
Dr. Norbert Riedel65
Eton Pharmaceuticals Independent Chairman of the Board
Compensation 210,850
Mr. Paul Maier75
Eton Pharmaceuticals Independent Director
Compensation 185,850
Mr. Charles Casamento77
Eton Pharmaceuticals Independent Director
Compensation 183,350
1
2

Eton Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Cardinal Health Stock
Cardinal Health
SupplierCustomer0,720,910,14-0,10-0,050,05
McKesson Stock
McKesson
SupplierCustomer0,43-0,48-0,42-0,35-0,76-0,73
Harrow Health Stock
Harrow Health
SupplierCustomer0,270,770,760,530,62-0,16
AmerisourceBergen Stock
AmerisourceBergen
SupplierCustomer0,240,040,07-0,21-0,68-0,74
Bausch Health Stock
Bausch Health
SupplierCustomer-0,170,900,900,760,730,12
Diurnal Group Stock
Diurnal Group
SupplierCustomer-0,680,770,320,300,570,47
1

Most common questions regarding Eton Pharmaceuticals

What values and corporate philosophy does Eton Pharmaceuticals represent?

Eton Pharmaceuticals Inc represents core values of innovation, quality, and patient care. The company is committed to delivering high-quality and innovative pharmaceutical products that meet the needs of patients and healthcare professionals. Eton Pharmaceuticals Inc embraces a patient-centric approach and aims to improve health outcomes by providing accessible and affordable medications. With a strong focus on research and development, Eton Pharmaceuticals Inc continuously strives to bring new and effective treatments to the market. The company's corporate philosophy revolves around integrity, transparency, and ethical business practices, ensuring trust and confidence among its stakeholders.

In which countries and regions is Eton Pharmaceuticals primarily present?

Eton Pharmaceuticals Inc is primarily present in the United States.

What significant milestones has the company Eton Pharmaceuticals achieved?

Eton Pharmaceuticals Inc has achieved several significant milestones. The company successfully received approval from the U.S. Food and Drug Administration (FDA) for multiple Abbreviated New Drug Applications (ANDAs). This includes the approval of important medications such as Topiramate Oral Solution and Levetiracetam Oral Solution. Eton Pharmaceuticals Inc has also entered into strategic partnerships and collaborations to further enhance its product portfolio and expand its market reach. These milestones highlight Eton Pharmaceuticals Inc's commitment to advancing the development and commercialization of high-quality pharmaceutical products.

What is the history and background of the company Eton Pharmaceuticals?

Eton Pharmaceuticals Inc is a pharmaceutical company based in Deer Park, Illinois, United States. Established in 2017, Eton Pharmaceuticals focuses on developing and marketing innovative drug products primarily in the United States. The company aims to address unmet medical needs, enhance patient accessibility, and improve medication delivery options. Eton Pharmaceuticals leverages its expertise in drug formulation and regulatory activities to create high-quality, affordable, and safe medications. With a strong commitment to improving patient care, Eton Pharmaceuticals continuously seeks opportunities to expand its product portfolio and contribute to advancing healthcare.

Who are the main competitors of Eton Pharmaceuticals in the market?

The main competitors of Eton Pharmaceuticals Inc in the market include various pharmaceutical companies such as Johnson & Johnson, Pfizer, Novartis, GlaxoSmithKline, and Eli Lilly.

In which industries is Eton Pharmaceuticals primarily active?

Eton Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

What is the business model of Eton Pharmaceuticals?

The business model of Eton Pharmaceuticals Inc revolves around developing and commercializing innovative and cost-effective drug products. Eton Pharmaceuticals focuses on improving the therapeutic availability of currently approved drugs through formulation enhancements. They aim to address unmet medical needs by developing and marketing high-quality generic pharmaceuticals for both branded and non-branded markets. Eton Pharmaceuticals utilizes a strategic combination of in-house research and development, acquisitions, collaborations, and licensing agreements to expand their product portfolio. By implementing their unique business model, Eton Pharmaceuticals Inc strives to provide affordable and accessible treatments to patients in need.

What is the P/E ratio of Eton Pharmaceuticals 2024?

The Eton Pharmaceuticals P/E ratio is -29.62.

What is the P/S ratio of Eton Pharmaceuticals 2024?

The Eton Pharmaceuticals P/S ratio is 3.13.

What is the AlleAktien quality score of Eton Pharmaceuticals?

The AlleAktien quality score for Eton Pharmaceuticals is 2/10.

What is the revenue of Eton Pharmaceuticals 2024?

The expected Eton Pharmaceuticals revenue is 37.23 M USD.

How high is the profit of Eton Pharmaceuticals 2024?

The expected Eton Pharmaceuticals profit is -3.93 M USD.

What is the business model of Eton Pharmaceuticals

Eton Pharmaceuticals Inc is a leading company in the pharmaceutical industry that focuses on the development and marketing of prescription drugs. The company's business model is based on identifying healthcare needs and developing innovative solutions for those needs. Eton Pharmaceuticals Inc is divided into several business areas, including drug development, manufacturing, registration, and marketing of medications. Drug development Eton Pharmaceuticals Inc heavily invests in research and development to develop high-quality and innovative medications for various diseases. The company specializes in developing drugs for rare diseases and diseases for which there is no effective treatment option yet. The company has a comprehensive portfolio of patented technologies and active ingredients used in drug manufacturing. Manufacturing Eton Pharmaceuticals Inc operates its own production facility for manufacturing active ingredients and medications. Manufacturing is done according to the highest quality standards and compliance with applicable regulations. The production facility is capable of producing both small and large quantities of medications to meet customer needs. Manufacturing is conducted under strict quality control and Good Manufacturing Practice (GMP) guidelines. Registration Eton Pharmaceuticals Inc possesses comprehensive knowledge of regulatory requirements and regulations in the pharmaceutical industry. The company utilizes this knowledge to manufacture safe and effective medications that meet the strict requirements of regulatory authorities. Eton Pharmaceuticals Inc works closely with authorities to achieve and implement medication approvals. Marketing Eton Pharmaceuticals Inc markets its products in the national and international market. The company works closely with distributors, wholesalers, pharmacies, and hospitals to distribute the products. Eton Pharmaceuticals Inc utilizes effective marketing strategies to create awareness for its products. The company employs a distribution channel strategy to achieve a broader reach. Products Eton Pharmaceuticals Inc offers a wide range of prescription medications for various diseases. This includes medications for rare diseases, colds, allergies, asthma, and other diseases for which there is no effective treatment option yet. Products like Alkindi Sprinkle, a medication for pediatric adrenal insufficiency, have already received US approval. Summary The business model of Eton Pharmaceuticals Inc is based on the development and marketing of high-quality and innovative prescription medications. The company has built comprehensive expertise in all areas of the pharmaceutical industry to deliver effective solutions for healthcare needs. The company pursues effective business strategies to enhance competitiveness and promote corporate growth.

What is the Eton Pharmaceuticals dividend?

Eton Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Eton Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Eton Pharmaceuticals or the company does not pay out a dividend.

What is the Eton Pharmaceuticals ISIN?

The ISIN of Eton Pharmaceuticals is US29772L1089.

What is the Eton Pharmaceuticals WKN?

The WKN of Eton Pharmaceuticals is A2N38G.

What is the Eton Pharmaceuticals ticker?

The ticker of Eton Pharmaceuticals is ETON.

How much dividend does Eton Pharmaceuticals pay?

Over the past 12 months, Eton Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Eton Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Eton Pharmaceuticals?

The current dividend yield of Eton Pharmaceuticals is .

When does Eton Pharmaceuticals pay dividends?

Eton Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Eton Pharmaceuticals?

Eton Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Eton Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Eton Pharmaceuticals located?

Eton Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Eton Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Eton Pharmaceuticals from 8/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/26/2024.

When did Eton Pharmaceuticals pay the last dividend?

The last dividend was paid out on 8/26/2024.

What was the dividend of Eton Pharmaceuticals in the year 2023?

In the year 2023, Eton Pharmaceuticals distributed 0 USD as dividends.

In which currency does Eton Pharmaceuticals pay out the dividend?

The dividends of Eton Pharmaceuticals are distributed in USD.

All fundamentals about Eton Pharmaceuticals

Our stock analysis for Eton Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Eton Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.